Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

UMIN000018246 - Lacticaseibacillus casei Shirota / Yakult & Type 2 Diabetes (T2D)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

Background

The movement of gut bacteria into the bloodstream might significantly contribute to the onset of insulin resistance in individuals with type 2 diabetes (1)

Study overview

UMIN000018246 - Lacticaseibacillus casei Shirota / Yakult & Type 2 Diabetes (T2D) is a clinical treatment trial to study Lacticaseibacillus casei Shirota / Yakult or no-probiotic in seventy randomized Japanese patients with type 2 diabetes (1)

Primary outcome measures

The change of gut microbiota before and after the study

The change of the detection rate of gut microbiota in the blood before and after the study (1)

Results

At the conclusion of the study, it was observed that the fe…

References (Sources)

Probiotic reduces bacterial translocation in type 2 diabetes mellitus: A randomised controlled study
Sato et al. 2017 Sci Rep 7(1): 12115

AI Chat

7/1/2026

Chat with our artificial intelligence:

Start chat!